Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis

Abstract

In a 24-week study of patients with cystic fibrosis, intermittent administration of inhaled tobramycin was well tolerated and improved pulmonary function, decreased the density of P. aeruginosa in sputum, and decreased the risk of hospitalization.